Demerol and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Demerol (meperidine hydrochloride), especially for people who are female, 40-49 old, also take Zometa, and have Osteoporosis.

The phase IV clinical study analyzes which people have Hearing loss when taking Demerol. It is created by eHealthMe based on reports of 12,407 people who have side effects when taking Demerol from the FDA, and is updated regularly.

What is Demerol?

Demerol has active ingredients of meperidine hydrochloride. It is often used in pain. eHealthMe is studying from 12,706 Demerol users. Check the latest studies of Demerol.

What is Hearing loss?

Hearing loss is found to be associated with 1,358 drugs and 2,381 conditions by eHealthMe. Check the latest studies of Hearing loss.

On Aug, 01, 2026

12,407 people reported to have side effects when taking Demerol.
Among them, 82 people (0.66%) have Hearing loss.

Among these 82 people:

What is the gender of people who have Hearing loss when taking Demerol? *

female: 72.6 %
male: 27.4 %

What is the age of people who have Hearing loss when taking Demerol? *

What are other drugs people take besides Demerol? *

What are other side effects people have besides Hearing loss? *

Stress And Anxiety: 71 people, 86.59%
Osteonecrosis Of Jaw (death of bone of jaw): 54 people, 65.85%
Back Pain: 48 people, 58.54%
Tooth Abscess (pus formation in tooth): 48 people, 58.54%
Injury: 45 people, 54.88%
Dyspnea (difficult or laboured breathing): 44 people, 53.66%
Anaemia (lack of blood): 44 people, 53.66%
Insomnia (sleeplessness): 44 people, 53.66%
Disability: 41 people, 50.00%
Nausea (feeling of having an urge to vomit): 40 people, 48.78%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 21 people, 25.61%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 14 people, 17.07%
Metastases To Bone (cancer spreads to bone): 14 people, 17.07%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 9 people, 10.98%
Bone Density Decreased: 5 people, 6.10%
Thrombocytopenia (decrease of platelets in blood): 4 people, 4.88%
Bone Loss: 4 people, 4.88%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 4 people, 4.88%
High Blood Pressure: 3 people, 3.66%
Breast Cancer Metastatic: 2 people, 2.44%

* Approximation only. Some reports may have incomplete information.

Do you take Demerol and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Demerol:

Demerol (12,706 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Demerol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,358 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,381 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on meperidine hydrochloride (the active ingredients of Demerol) and Demerol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.